Safety, efficacy and biology of the gp100 TCR-based bispecific T cell redirector, IMCgp100 in advanced uveal melanoma in two Phase 1 trialsR Carvajal,T Sato,A N Shoushtari,J Sacco,P Nathan,M Orloff,P Corrie,N Steven,J Evans,J Infante, M Sznol,C Mulatero,O Hamid, L Hernandez-Aya, N Little,C McAlpine, D Krige,N J Hassan,S Patel, Hulstine A-M., C M Coughlin, M R MiddletonJOURNAL FOR IMMUNOTHERAPY OF CANCER（2017）引用 0|浏览19暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
